Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267


News SummaryMost relevantAll newsSector newsTweets 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
01:01p NOVARTIS : FDA accepts application for generic version of Advair Diskus
10:57a Oil keeps a lid on European shares, Novartis drives health stocks
07:16a NOVARTIS : Phase III study shows ACZ885 (canakinumab) reduces cardiovascular ris..
06/21 NOVARTIS : achieves important regulatory milestone for AMG 334 (erenumab) in mig..
06/20 Novartis eye drug works with fewer injections than rival
06/20 Inhalation & Nasal Spray Generic Drugs Market - Global Trends, Market Share, ..
06/20 NOVARTIS : secures European approval for cancer treatment
06/20 NOVARTIS : MabThera biosimilar wins EU nod
06/20 NOVARTIS : RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patien..
06/20 NOVARTIS : real world study shows almost half of chronic urticaria patients are ..
More news
Sector news : Pharmaceuticals - NEC
06:27p MYLAN : shareholders vote against executive pay, re-elect board
08:48aDJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21 Healthcare stocks rally as Senate set to unveil bill
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
06/21DJR. JOHNSON : Missouri Files Its Own Suit Against Opioid-Painkiller Producers -- ..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:27p Drug stocks rally on GOP draft of healthcare bill
11:33a Cantos Could Make Ilaris A Blockbuster
10:52a Regeneron clarifies canakinumab royalty deal with Novartis
10:13a GILEAD : The Conundrum
Financials ($)
Sales 2017 48 351 M
EBIT 2017 11 671 M
Net income 2017 7 498 M
Debt 2017 15 479 M
Yield 2017 3,44%
P/E ratio 2017 24,67
P/E ratio 2018 21,75
EV / Sales 2017 4,75x
EV / Sales 2018 4,54x
Capitalization 214 313 M
More Financials
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 80,7 $
Spread / Average Target -1,7%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.69%214 091
JOHNSON & JOHNSON16.50%361 566
ROCHE HOLDING LTD.8.81%224 305
PFIZER4.31%199 854
MERCK AND COMPANY11.19%176 500
SANOFI12.56%121 796
More Results